Kezar Life Sciences Files 8-K on Financial Condition

TL;DR

**Kezar Life Sciences just dropped an 8-K about their financials, get ready for an update on their money situation.**

AI Summary

Kezar Life Sciences, Inc. filed an 8-K on January 8, 2024, under Item 2.02, 'Results of Operations and Financial Condition.' This filing indicates that the company is providing an update on its financial performance, likely through an earnings release or similar announcement. For investors, this matters because it offers a timely look into the company's financial health and operational efficiency, which can directly influence stock price and future investment decisions.

Why It Matters

This filing signals an upcoming or concurrent disclosure of Kezar Life Sciences' financial results, providing crucial transparency for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This 8-K is a standard disclosure of financial information, not indicating any immediate negative events or significant changes in company operations.

Analyst Insight

A smart investor would look for the specific financial results or press release that this 8-K refers to under Item 2.02 to understand the company's latest performance and financial health.

Key Players & Entities

• Kezar Life Sciences, Inc. (company) — the registrant filing the 8-K
• January 08, 2024 (date) — date of earliest event reported
• 001-38542 (other) — Commission File Number
• 47-3366145 (other) — IRS Employer Identification No.
• KZR (other) — Trading Symbol for Common Stock
• The Nasdaq Stock Market LLC (other) — exchange where Common Stock is registered

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value KZR The Nasdaq Stock Mark
• $201.4 million — of December 31, 2023 were approximately $201.4 million and that it had 72.8 million shares of

Filing Documents

• kzr-20240108.htm (8-K) — 34KB
• 0000950170-24-002728.txt ( ) — 141KB
• kzr-20240108.xsd (EX-101.SCH) — 23KB
• kzr-20240108_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Kezar Life Sciences, Inc. (the “Company”) preliminarily estimates that its cash, cash equivalents and marketable securities as of December 31, 2023 were approximately $201.4 million and that it had 72.8 million shares of common stock outstanding as of December 31, 2023. These preliminary estimates are not a comprehensive statement of the Company’s financial results for the year ended December 31, 2023 and have not been audited, reviewed, or compiled by its independent registered public accounting firm. The Company’s actual consolidated cash, cash equivalents and marketable securities balance and shares of common stock outstanding as of December 31, 2023 may differ from these estimates due to the completion of the Company’s year-end closing and auditing procedures. The information provided in this Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kezar Life Sciences, Inc. Date: January 8, 2024 By: /s/ Marc L. Belsky Marc L. Belsky Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR